Turn Therapeutics (TTRX) EBITDA (2024 - 2026)

Turn Therapeutics' EBITDA history runs 3 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• On a quarterly basis, EBITDA fell 223.68% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$5.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$5.9 million, down 226.0% from the prior year.
• EBITDA climbed to -$1.2 million in Q1 2026 per TTRX's latest filing, from -$2.2 million in the prior quarter.
• Across five years, EBITDA topped out at -$328957.0 in Q4 2024 and bottomed at -$2.2 million in Q4 2025.
• The 3-year median for EBITDA is -$959567.5 (2024), against an average of -$1.1 million.
• Biggest YoY gain for EBITDA was 184.34% in 2025; the steepest drop was 566.83% in 2025.
• Year by year, EBITDA stood at -$328957.0 in 2024, then tumbled by 566.83% to -$2.2 million in 2025, then soared by 43.19% to -$1.2 million in 2026.
• Per Business Quant, the three latest TTRX EBITDA figures stand at -$1.2 million (Q1 2026), -$2.2 million (Q4 2025), and -$1.9 million (Q3 2025).